Cytomegalovirus (CMV)

Cytomegalovirus (CMV)

Overview

The Bio-Rad CMV kits utilize EIA technology for the determination of IgM and IgG antibodies to CMV
Read full description

Description

Description

CMV infection remains difficult to identify by symptoms alone and laboratory diagnosis is needed to establish the immune status of the patient and check for seroconversion. The immune response to CMV involves synthesis of IgM antibodies several weeks after primary infection and one week later, IgG antibodies appear.

Primary CMV infection in adults is often manifested by a mononucleosis-like syndrome and is usually self-limiting. However, in neonates and immuno compromised individuals, CMV can be debilitating and life-threatening. Seronegative women who contract the virus during the pregnancy may transmit the virus to the foetus.

Approximately 0.5 to 2.5% of newborn infants are identified each year with congenital Cytomegalovirus infection. Fewer than 5% of congenitally-infected infants develop severe disease. After primary infection, CMV enters a latent state and can be detected in B lymphocytes. Then, unlike rubella and toxoplasmosis, a reactivation (secondary infection) can occur.

Ordering

Ordering

items

Use the filters below to refine results!

Image
cmd_25177_tn.jpg
(Discontinued) CMV IgG EIA Kit
25177
96 enzyme immunoassays for IgG antibodies to cytomegalovirus; this kit may not be used for avidity testing
Image
cmd_25178_tn.jpg
(Discontinued) CMV IgM EIA Kit
25178
96 enzyme immunoassays for IgM antibodies to cytomegalovirus; this kit may not be used for avidity testing